With Market at Inflection Point, Diagnostics Companies Should Consider New Business Models, Novel Markers, Ultrasensitive Platforms and Multiplex Technologies for Future Success
BOSTON & SAN FRANCISCO--(BUSINESS WIRE)-- With the market for certain advanced medical testing methods poised for accelerated growth, many diagnostics companies must adjust their portfolios and their business models in order to position themselves for growth, according to a Scientia Advisors review of the global immunoassay market released today.
Immunoassays are laboratory tests used to identify and quantify blood components associated with particular diseases. Immunoassays are a key growth area within in vitro diagnostics (tests conducted in laboratories, as opposed to those carried out in living organisms).
“Most current immunoassay technologies focus on detecting one or several proteins in a patient’s blood/serum or other samples,” said Arshad Ahmed, a partner at Scientia Advisors. “However, novel markers and new technologies that can detect and measure multiple markers simultaneously will become increasingly available in the next several years.” Such advanced technologies—already used in diagnosing and treating infectious diseases, cancer, and kidney injury—are faster, more accurate and more cost-effective than many “traditional” tests. As a result, they may command higher prices and are driving growth in the overall immunoassay market.
What is more, for diagnostics players, marketing and business models are changing, according to Ahmed. Pharmaceutical companies are beginning to incorporate diagnostic tests into their sales processes. And certain diagnostics companies are adopting a “sole service provider” model—in which tests are marketed directly to physicians and performed in company-run laboratories.
In light of these changes, “it is crucial that companies in the diagnostics space re-examine their business strategies in order to compete successfully in the coming years,” Ahmed said.
Review highlights:
- The $7.7B immunoassay market comprises one fifth of the $37B in vitro diagnostics (IVD) market. While the IVD market is growing modestly at 7% a year, the immunoassay market, which has experienced a compound annual growth rate (CAGR) of approximately 6% since 2007, is expected to grow at a 9% CAGR through 2012, largely due to technology advancements.
- Growth in the immunoassay market will be driven by the emergence of (1) ultra-sensitive platforms, which enable detection of analytes at minute concentrations; (2) multiplex technologies, which allow simultaneous analysis of multiple compounds and (3) novel biomarkers that increase the accuracy and efficiency of diagnosis or treatment.
- Emerging economies, such as China’s, are experiencing robust immunoassay market growth.
- Personalized medicine and new business models such as the bundling of immunoassays with marketed drugs and the sole service provider are changing industry paradigms.
Scientia’s study, Strategic Review of Immunoassays: Seeing Beyond the Market Inflection Point, is available for download at no cost at www.scientiaadv.com.
Scientia Advisors, based in Boston and San Francisco, is a management consulting firm specializing in growth strategies for major and emerging companies in health care, life sciences, biotechnology, and nutrition.
CONTACT:
Harris Communications Group
Anita M. Harris, 617-576-0906
[email protected]
or
Scientia Advisors
Anne-Sophie Dankens, 617-299-3026
KEYWORDS: United States North America California Massachusetts
INDUSTRY KEYWORDS: Practice Management Health Biotechnology Clinical Trials Hospitals Infectious Diseases Medical Devices Oncology
MEDIA:
| Logo |